BioCatalyst

RYZ101, Everolimus, Sunitinib, Octreotide — catalyst calendar

1 verified catalyst event(s) referencing RYZ101, Everolimus, Sunitinib, Octreotide, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 2mo
ESTIMATED
 READOUT
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated
Phase 3 · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
 RayzeBio, Inc. RYZ101, Everolimus, Sunitinib, Octreotid ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.